Page 616 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

594 PART IV Specific Malignancies in the Small Animal Patient

357. Ham K, Greenfield CL, Barger A, et al.: Validation of a rapid para- 374. Jackson TC, Debey B, Lindbloom-Hawley S, et al.: Cellular and
thyroid hormone assay and intraoperative measurement of para- molecular characterization of a feline insulinoma, J Vet Intern Med
thyroid hormone in dogs with benign naturally occurring primary 23:383–387, 2009.
VetBooks.ir 358. Chew DJ, Nagode LA, Schenck PA: Treatment of hypoparathy- 375. Nelson RW: Beta-cell neoplasia: insulinoma. In Feldman EC, Nel-
hyperparathyroidism, Vet Surg 38:122–132, 2009.
son RW, Reusch CE, et al.: Canine and feline endocrinology, ed 4,
roidism. In Bonagura JD, Twedt DC, editors: Kirk’s current veteri-
St. Louis, 2015, Elsevier, pp 348–375.
nary therapy XIV, St. Louis, 2009, Saunders Elsevier, pp 241–247. 376. Hawkins KL, Summers BA, Kuhajda FP, et al.: Immunocytochem-
359. Armstrong AJ, Hauptman JG, Stanley BJ, et al.: Effect of prophy- istry of normal pancreatic islets and spontaneous islet cell tumors in
lactic calcitriol administration on serum ionized calcium concen- dogs, Vet Pathol 24:170–179, 1987.
trations after parathyroidectomy: 78 cases (2005-2015), J Vet Intern 377. Myers 3rd NC, Andrews GA, Chard-Bergstrom C: Chromogranin
Med 32:99–106, 2018. A plasma concentration and expression in pancreatic islet cell
360. Dear JD, Kass PH, Della Maggiore AM, et al.: Association of tumors of dogs and cats, Am J Vet Res 58:615–620, 1997.
hypercalcemia before treatment with hypocalcemia after treat- 378. Minkus G, Jutting U, Aubele M, et al.: Canine neuroendocrine
ment in dogs with primary hyperparathyroidism, J Vet Intern Med tumors of the pancreas: a study using image analysis techniques for
31:349–354, 2017. the discrimination of metastatic versus nonmetastatic tumors, Vet
361. Milovancev M, Schmiedt CW: Preoperative factors associated with Pathol 34:138–145, 1997.
postoperative hypocalcemia in dogs with primary hyperparathy- 379. Madarame H, Kayanuma H, Shida T, et al.: Retrospective study of
roidism that underwent parathyroidectomy: 62 cases (2004-2009), canine insulinomas: eight cases (2005-2008), J Vet Med Sci 71:905–
J Am Vet Med Assoc 507–515, 2013. 911, 2009.
362. Arbaugh M, Smeak D, Monnet E: Evaluation of preoperative 380. Buishand FO, van Erp MG, Groenveld HA, et al.: Expression of
serum concentrations of ionized calcium and parathyroid hormone insulin-like growth factor-1 by canine insulinomas and their metas-
as predictors of hypocalcemia following parathyroidectomy in dogs tases, Vet J, 2011.
with primary hyperparathyroidism: 17 cases (2001-2009), J Am Vet 381. Buishand FO, Kirpensteijn J, Jaarsma AA, et al.: Gene expression
Med Assoc 241:233–236, 2012. profiling of primary canine insulinomas and their metastases, Vet J
363. Reinhart JM, Nuth EK, Byers CG, et al.: Pre-operative fibrous 197:192–197, 2013.
osteodystrophy and severe, refractory, post-operative hypocalce- 382. Buishand FO, Kik M, Kirpensteijn J: Evaluation of clinico-path-
mia following parathyroidectomy in a dog, Can Vet J 56:867–871, ological criteria and the Ki67 index as prognostic indicators in
2015. canine insulinoma, Vet J 185:62–67, 2010.
364. Witteveen JE, van Thiel S, Romijn JA, et al.: Hungry bone syn- 383. Leifer CE, Peterson ME, Matus RE: Insulin-secreting tumor: diag-
drome: still a challenge in the post-operative management of pri- nosis and medical and surgical management in 55 dogs, J Am Vet
mary hyperparathyroidism: a systematic review of the literature, Med Assoc 188:60–64, 1986.
Eur J Endocrinol 168:R45–53, 2013. 384. Caywood DD, Klausner JS, O’Leary TP, et al.: Pancreatic insulin-
365. Lee IT, Sheu WH, Tu ST, et al.: Bisphosphonate pretreatment secreting neoplasms: clinical, diagnostic, and prognostic features in
attenuates hungry bone syndrome postoperatively in subjects with 73 dogs, J Am Anim Hosp Assoc 24:577–584, 1988.
primary hyperparathyroidism, J Bone Miner Metab 24:255–258, 385. Steiner JM, Bruyette DS: Canine insulinoma, Compend Contin
2006. Educ Vet 18:13–25, 1996.
366. Mahajan A, Narayanan M, Jaffers G, et al.: Hypoparathyroidism 386. Trifonidou MA, Kirpensteijn J, Robben JH: A retrospective evalu-
associated with severe mineral bone disease postrenal transplanta- ation of 51 dogs with insulinoma, Vet Q 20(Suppl 1):S114–115,
tion, treated successfully with recombinant PTH, Hemodial Int 1998.
13:547–550, 2009. 387. Tobin RL, Nelson RW, Lucroy MD, et al.: Outcome of surgical
367. Graham KJ, Wilkinson M, Culvenor J, et al.: Intraoperative para- versus medical treatment of dogs with beta cell neoplasia: 39 cases
thyroid hormone concentration to confirm removal of hypersecre- (1990-1997), J Am Vet Med Assoc 215:226–230, 1999.
tory parathyroid tissue and time to postoperative normocalcaemia 388. Robben JH, Visser-Wisselaar HA, Rutteman GR, et al.: In vitro
in nine dogs with primary hyperparathyroidism, Aust Vet J 90:203– and in vivo detection of functional somatostatin receptors in canine
209, 2012. insulinomas, J Nucl Med 38:1036–1042, 1997.
368. Pollard RE, Long CD, Nelson RW, et al.: Percutaneous ultraso- 389. Robben JH, Van Garderen E, Mol JA, et al.: Locally produced
nographically guided radiofrequency heat ablation for treatment growth hormone in canine insulinomas, Mol Cell Endocrinol
of primary hyperparathyroidism in dogs, J Am Vet Med Assoc 197:187–195, 2002.
218:1106–1110, 2001. 390. Schermerhorn T: Canine insulinoma as a model for studying
369. Bucy D, Pollard R, Nelson R: Analysis of factors affecting outcome molecular genetics of tumorigenesis and metastasis, Vet J 197:126–
of ultrasound-guided radiofrequency heat ablation for treatment 127, 2013.
of primary hyperparathyroidism in dogs, Vet Radiol Ultrasound 391. Buishand FO, Visser J, Kik M, et al.: Evaluation of prognostic indi-
58:83–89, 2017. cators using validated canine insulinoma tissue microarrays, Vet J
370. Long CD, Goldstein RE, Hornof WJ, et al.: Percutaneous 201:57–63, 2014.
ultrasound-guided chemical parathyroid ablation for treatment 392. Polton GA, White RN, Brearley MJ, et al.: Improved survival in
of primary hyperparathyroidism in dogs, J Am Vet Med Assoc a retrospective cohort of 28 dogs with insulinoma, J Small Anim
215:217–221, 1999. Pract 48:151–156, 2007.
371. Guttin T, Knox VWt, Diroff JS: Outcomes for dogs with primary 393. Shahar R, Rousseaux C, Steiss J: Peripheral polyneuropathy in a
hyperparathyroidism following treatment with percutaneous ultra- dog with functional islet B-cell tumor and widespread metastasis, J
sound-guided ethanol ablation of presumed functional parathyroid Am Vet Med Assoc 187:175–177, 1985.
nodules: 27 cases (2008-2011), J Am Vet Med Assoc 247:771–777, 394. Braund KG, McGuire JA, Amling KA, et al.: Peripheral neuropathy
2015. associated with malignant neoplasms in dogs, Vet Pathol 24:16–21,
372. Batcher E, Madaj P, Gianoukakis AG: Pancreatic neuroendocrine 1987.
tumors, Endocr Res 36:35–43, 2011. 395. Braund KG, Steiss JE, Amling KA, et al.: Insulinoma and subclini-
373. Schaub S, Wigger A: Ultrasound-aided diagnosis of an insulinoma cal peripheral neuropathy in two dogs, J Vet Intern Med 1:86–90,
in a cat, Tierarztl Prax Ausg K Kleintiere Heimtiere 41:338–342, 1987.
2013.